Alere recalls 800,000 Triage tests on quality control issues
This article was originally published in Clinica
Executive Summary
Alere has recalled 803,000 of its Triage tests after problems with quality control testing and performance of the diagnostics. The recall affects a total of 104 lots comprising 287,000 Alere Triage BNP (B-type natriuretic peptide) tests, 46,000 Alere Triage D-dimer tests and 470,000 Alere Triage cardiology panel tests, according to a company filing with the US Securities and Exchange Commission (SEC).
You may also be interested in...
Alere's $33.2m Settlement May Reflect Growing US Fed Focus On Dx
Abbott subsidiary Alere is paying $33.2m to settle allegations the company knowingly allowed hospitals to bill for tests performed using unreliable diagnostics marketed by the company. It's one of the first times that US DoJ has held a company responsible for false claims filed due to faulty test results.
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.